CASI Pharmaceuticals Receives Orphan Drug Designation For Liver Cancer Drug
October 14, 2015 at 17:58 PM EDT
Shares of CASI Pharmaceuticals, Inc. ended the day up 40%, after the company announced that it had received Orphan Drug Designation from the European Union.
